Oral Peptide Icotrokinra Outperforms Placebo in Ulcerative Colitis

Trial Results for Oral Icotrokinra at 12 Weeks

Oral icotrokinra produced higher rates of clinical response than placebo in adults with moderately to severely active ulcerative colitis. The findings come from a Phase 2, double-blind, randomized controlled trial published in the New England Journal of Medicine. Lead investigator Maria T. Abreu, M.D., from Cedars-Sinai in Los Angeles, evaluated three daily doses alongside an inactive control.

The trial enrolled 252 participants split across four arms. Investigators assigned 63 participants to 400 mg daily, 62 to 200 mg daily, 64 to 100 mg daily, and 63 to placebo. At week 12, all three active doses showed superior clinical response compared to placebo.

Response rates followed a clear dose pattern. Rates reached 63% in the 400-mg group, 58% in the 200-mg group, and 55% in the 100-mg group, compared to 27% in the placebo group.

Remission and Tissue Outcomes for the 400-Milligram Dose

Participants receiving 400 mg daily achieved higher rates across all secondary clinical markers at week 12 than those on placebo. Clinical remission occurred in 30% of the 400-mg cohort compared to 11% on placebo. Symptomatic remission reached 46% with the 400-mg dose versus 19% in the placebo arm.

Endoscopic improvement occurred in 37% of participants on 400 mg compared to 14% on placebo. These mucosal findings show tissue-level changes alongside patient-reported symptom relief.

Abreu noted the drug remained effective in participants who had not responded to prior therapies. Because icotrokinra is taken orally, the candidate provides an alternative delivery route to injected biologics.

Safety Profile and Adverse Events through Week 28

Overall adverse event rates through week 28 were similar between active treatment and placebo arms. Adverse events occurred in 60% of the 400-mg group, 66% of the 200-mg group, 66% of the 100-mg group, and 62% of the placebo group.

Serious adverse events remained low across the active arms. Investigators documented serious events in 2% of the 400-mg arm, 5% of the 200-mg arm, and 0% of the 100-mg arm. The placebo group recorded a 10% rate of serious adverse events over the same window.

Biological Mechanism and Current Evidence Limitations

Icotrokinra operates as an oral peptide that blocks the interleukin-23 receptor (IL-23R). Targeted peptides often require injection because digestive enzymes degrade protein chains in the gastrointestinal tract. Delivering an interleukin-23 inhibitor as an intact oral pill represents an alternative delivery approach for chronic gut inflammation.

These data reflect an initial Phase 2 trial running through 28 weeks of safety tracking. Long-term durability and rare side effects require confirmation in larger Phase 3 trials before regulatory agencies evaluate the medication. Patients managing ulcerative colitis should discuss existing approved therapies with their gastroenterologist while investigational peptide trials progress.